TIDMOBD
RNS Number : 0428K
Oxford BioDynamics PLC
30 December 2020
Oxford BioDynamics Plc
Board change
Oxford, UK - 30 December 2020 - Oxford BioDynamics Plc (AIM:
OBD, the Company), a biotechnology company developing precision
medicine tests for personalized healthcare based on the EpiSwitch
(TM) 3D genomics platform , announces that Christian Hoyer Millar
will retire from the Board of Directors on 31 December 2020.
Christian co-founded OBD along with Dr Alexandre Akoulitchev and
Dr Aroul Ramadass in 2008 and as CEO was instrumental in helping to
develop the Company into a best-in-class global 3D Genomics
innovator.
Earlier this year, he brought in his successor as CEO, Dr Jon
Burrows and moved to an Executive Director role. Christian has been
a major force in championing OBD's technology and the strong ties
it has built with big pharma and academia. Without his involvement
the Company would not have the exceptional platform for future
growth and commercialization that it does today.
Dr. Jon Burrows, CEO of Oxford BioDynamics commented: "Christian
has done a marvelous job at OBD and will be missed. During his
tenure, the EpiSwitch (TM) platform has been proven and we are all
immensely excited about the Company's future. On behalf of the
Company, I wish him and his family all the best for the
future".
Christian Hoyer Millar said, "I leave OBD, at a time where it is
uniquely positioned to drive the commercialization and application
of its platform technology. I wish Jon and all my former colleagues
at the Company the very best for the future."
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Alexandre Akoulitchev, CSO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20 7408 4090
Broker
Edward Mansfield / John More
Instinctif Partners Tel: +44 (0)20 3727 1000
Melanie Toyne-Sewell / Agnes Stephens OxfordBioDynamics@instinctif.com
/ Katie Duffell
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(TM), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial team in the US and
a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(TM)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(TM) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(TM) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(TM) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its leading technology to
develop a pipeline of tests in a wide range of indications, such as
Covid-19 severity, immuno-oncology, neurodegenerative and
autoimmune diseases.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABSBDDSBDDGGC
(END) Dow Jones Newswires
December 30, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Biodynamics (LSE:OBD)
Storico
Da Apr 2023 a Apr 2024
